Business Overview - The company is a provider of innovative blood purification products, specializing in the research, development, production, and sales of blood perfusion-related products [3] - Products include single-use blood perfusion devices, single-use plasma bilirubin adsorbers, DNA immunoadsorption columns, and blood purification equipment, widely used in treating uremia, poisoning, severe liver diseases, autoimmune diseases, multiple organ failure, and ICU cases [3] - Blood purification technology is increasingly used as a third treatment option alongside surgery and medication [3] - The company's products are available in over 3,600 hospitals nationwide, with growing brand influence and rapid sales growth [3] Financial Performance - In 2017, the company achieved revenue of 718,491,131.27 yuan, a year-on-year increase of 32.16%, and net profit attributable to shareholders of 284,413,992.87 yuan, a year-on-year increase of 40.72% [3] - Key financial indicators for 2017 include a gross margin of 84.14%, net margin of 39.59%, operating cash flow of 304 million yuan, ROE of 22.21%, and debt-to-asset ratio of 18.26% [3] - In Q1 2018, revenue reached 207 million yuan, a year-on-year increase of 39.60%, and net profit attributable to shareholders was 89,976,900 yuan, a year-on-year increase of 50.89% [4] Core Competencies - A competitive talent team that shares in the company's growth [4] - Leading R&D capabilities and technological advantages [4] - Advanced marketing methods and a well-structured marketing organization [4] Future Development Plans - Focus on the blood purification field, deepen the domestic market, and expand overseas markets [4] - Develop new products to meet clinical needs and seek high-quality M&A targets to enhance product lines and technological capabilities [4] - Aim to build a comprehensive blood purification value chain and become a world-class high-tech medical technology enterprise group [4] Sales and Marketing - The company employs a buyout sales model through distributors, who then sell to hospital terminals [4] - Marketing strategies include demand stimulation, product promotion, and brand enhancement, supported by a self-built marketing team [4] - As of the end of 2017, the company had over 600 marketing personnel, with plans to expand the team in 2018 [5] Pricing and Technology - In 2017, the company reduced the price of HA130 from 680 yuan to 599 yuan, with no further price reduction plans [5] - The company holds relevant product patents and has mastered key technologies such as carrier synthesis, pore formation, activation, ligand grafting, and bio-film production [5] - The production process involves over 20 steps, each with strict control procedures to ensure product effectiveness, safety, and stability [5] Investor Communication - The company ensured transparent and fair communication with investors, adhering to information disclosure regulations and signing the required commitment letter [6]

编号：2018-006 证券代码：300529 证券简称：健帆生物 珠海健帆生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|------------------------|---------------------------------| | | | | | 投资者关系活动类 | ■ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 北信瑞丰 陈乐华 | | | 员姓名 | 毕马威企业融资部 | 姚辑 | | | 渤海汇金 纪纲 | | | | 财通证券 黄兵 | | | | 超嬴投资 吴佳璇 | | | | 诚盛资管 杨洁 | | | | 大成基金 魏庆国 | | | | 东吴证券 全铭 | | | | 方正证券 黄鹏 | | | | 方正自营 卫雯清 | | | | 工银瑞信 谭冬寒 | | | | 古槐资本 任嘉 | | | | 光大永明 ...

编号：2018-004 证券代码：300529 证券简称：健帆生物 珠海健帆生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|-------------------|---------------------------------| | | | | | 投资者关系活动类 | ■ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 闫小龙 百毅资本 | | | 员姓名 | 庞中金 | 宝盈资产管理 | | | 陈洋 | 北京方圆金鼎投资管理有限公司 | | | 李冰 | 碧桂园集团 | | | 蔡滨 博时基金 | | | | 陈雷 博时基金 | | | | 兰乔 博时基金 | | | | 沙炜 博时基金 | | | | 汤凌峰 | 大连华讯投资有限公司 | | | 葛云霄 鼎诺投资 | | | | 罗钟祥 东方证券 | | | | 赖小锋 东莞证券 | ...

编号：2018-005 证券代码：300529 证券简称：健帆生物 珠海健帆生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|-------------------|---------------------------------| | | | | | 投资者关系活动类 | ■ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 爱建证券 章孝林 | | | 员姓名 | 百域资本 唐林凤 | | | | 宝盈基金 杨思亮 | | | | 碧云资本 孙亮 | | | | 财通基金 凌晨 | | | | 财通基金 陆玲玲 | | | | 财通资管 朱晨 | | | | 常春藤资产 刘涛 | | | | 慈阳投资 王镜程 | | | | 从容投资 罗凌 | | | | 鼎锋资本 严洋 | | | | 东北证券 王鑫园 | | | | 东北证券 齐震 | | ...

编号：2018-003 证券代码：300529 证券简称：健帆生物 珠海健帆生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|------------------------|---------------------------------| | | | | | 投资者关系活动类 | ■ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 财通证券 沈瑞 | | | 员姓名 | 光证资管 曾炳祥 | | | | 东北证券 崔洁铭 | | | | 东方证券资管 | 李峰 | | | 东吴证券 许汪洋 | | | | 方正证券 周小刚 | | | | 方正证券 陈家华 | | | | 广发基金 王瑞冬 | | | | 广发基金 吴兴武 | | | | 广发证券 马帅 | | | | 广发证券 李奔 | | | | 广证恒生 冯俊曦 | | | | 国泰基金 ...

编号：2018-007 证券代码：300529 证券简称：健帆生物 珠海健帆生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|--------------------------|----------------------------------------------------| | | | | | 投资者关系活动类 | ■ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 罗佳荣 广发证券 | | | 员姓名 | 白玉 浙商基金 | | | | 孙笑悦 富国基金 | | | | 高敏 望正资本 | | | | 陈曦 广发信德 | | | 时间 | 2018 年 11 月 13 | 日 | | 地点 | 公司研发大楼 | | | 上市公司接待人员 | 董事长兼总经理董凡先生 | | | 姓名 | 董事会秘书张明渊先生 | | | 投资者关系活动主 ...

Group 1: Impact of Policies on Products - The company's main product, disposable blood perfusion devices, is currently not included in the "centralized procurement" scope, and it is expected that it will not be included in the short term due to its low clinical usage and procurement volume [2][3] - The blood perfusion device does not meet the characteristics required for centralized procurement, such as high clinical usage, high procurement amounts, and maturity in clinical use [2][3] - If the product is included in centralized procurement in the future, sales are expected to increase significantly, enhancing the company's market share and profitability [3] Group 2: DRGs and Company Operations - The DRG (Diagnosis-Related Group) system is primarily applicable to acute inpatient cases and is not suitable for outpatient cases, which is relevant for the company's blood perfusion devices used in outpatient settings [3][4] - Most patients using the company's blood perfusion devices are outpatients, making them ineligible for DRG classification [3] Group 3: Business Development and Future Plans - The company is optimistic about its liver disease business, which has shown recovery in the second half of 2020 after the initial impact of COVID-19 [4] - Future development will focus on leveraging experience from the kidney disease sector to enhance the liver disease business [4] - The company plans to promote new products like dialysis machines and dialysis solutions through existing customer networks, emphasizing high-quality products and competitive pricing [4][5] Group 4: Long-term Strategy and Market Positioning - Over the next five years, the company aims to deepen its focus on kidney and liver disease, developing a comprehensive blood purification industry chain that includes medical devices, consumables, and services [5] - The company has initiated insurance products for kidney disease patients, enhancing customer loyalty and expanding its service offerings [5] - Future strategies include utilizing capital market resources and potential acquisitions to strengthen the company's unique blood purification industry chain [5]

编号：2021-003 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | ...

编号：2021-005 1 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 | □ 业绩说明会 | | 系活动类 | □ 新闻发布会 | □ 路演活动 | | 别 | □ 现场参观 | √ 其他（电话会议） | | | 广发证券：罗佳荣、漆经纬 | | | 参与单位 | | 博时基金、华泰柏瑞、兴业基金、华夏基金、长城基金、工银瑞信、 | | 名 ...

编号：2021-006 1 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------| | | √ 特定对象调研 □ | 分析师会议 | | 投资者关 | □ 媒体采访 □ | 业绩说明会 | | 系活动类 | □ 新闻发布会 □ | 路演活动 | | 别 | □ 现场参观 □ | 其他 | | 参与单位 | | 广发基金、中信产业基金、安信证券、兴业证券、中信建投、华泰证 | | 名称及人 | | 券、宝盈基金、富国基金、融通基金、华夏基金、招商基金、嘉实基 | | 员姓名 | 资、前海资管等 70 | 金、中信建投、兴全基金、东吴资管、国金证券、中欧基金、徐星投 ...